Brain stimulation device demonstrates safety, seizure reduction

Researchers present the findings from a 2-year multicenter randomized double blinded controlled clinical study and a 7 year long-term treatment study of the NeuroPace RNS System at the American Epilepsy Society’s 67th Annual Meeting. The RNS System is a novel,…

Researchers present the findings from a 2-year multicenter randomized double blinded controlled clinical study and a 7 year long-term treatment study of the NeuroPace RNS System at the American Epilepsy Society’s 67th Annual Meeting. The RNS System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to detect abnormal electrical activity in the brain and respond by delivering imperceptible levels of electrical stimulation to normalize brain activity before an individual experiences seizures. NeuroPace received pre-market approval from the U.S. Food and Drug Administration in November.

The RNS System has been evaluated in three clinical trials, including a prospective, randomized, double-blinded, sham stimulation controlled pivotal study. The RNS System has demonstrated safety and effectiveness in patients who average three or more disabling seizures per month over the three most recent months (with no month with fewer than two seizures), and has not been evaluated in patients with less frequent seizures. The pivotal study primary effectiveness endpoint was met by demonstrating a 37.9 percent reduction in seizure frequency in patients treated with responsive stimulation compared to a 17.3 percent reduction in patients who were implanted with the device but were not receiving responsive stimulation during a three month blinded period. The difference is statistically significant (p=0.012). For those subjects who reached two years post-implant, 55% of the subjects experienced a 50% or greater reduction in seizures.

An evaluation of the 191 implanted patients from the pivotal study found that there was no difference between the active and sham stimulation groups in the rate of adverse events, including depression, memory impairment and anxiety. There were no serious unanticipated device related adverse events reported in any of the clinical trials. Although there can be no assurances that additional long-term data will not reveal new adverse information presently unknown to NeuroPace, two year data shows no increase or worsening of adverse events.
“The results of the pivotal study clearly demonstrate that the safety and efficacy of the RNS System is sustained over two years. Additional data about safety and efficacy beyond two years is being collected in a long-term follow-up study,” said Martha Morrell, MD, NeuroPace Chief Medical Officer and Clinical Professor of Neurology at Stanford University.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is based on materials provided by American Epilepsy Society (AES), via Newswise.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Search ScienceDaily
Number of stories in archives: 148,304

 

Interested in ad-free access? If you’d like to read ScienceDaily without ads, let us know!

more breaking science news

Social Networks
Follow ScienceDaily on Facebook, Twitter, and Google:

Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

Breaking News
… from NewsDaily.com

more science news
In Other News …
more top news
Science Video News

Pinpointing Problems In The Brain
Doctors are now using a new kind of brain scan called magnetoencephalography (MEG), which measures brain activity in real time. In some cases, MEG. …  > full story

Strange Science News
Free Subscriptions
… from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:
Email Newsletters
RSS Newsfeeds
Feedback
… we want to hear from you!

Tell us what you think of ScienceDaily — we welcome both positive and negative comments. Have any problems using the site? Questions?
Leave Feedback